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Context: Selenium status may have direct effects on bone and indirect effects through changes in
thyroid hormone sensitivity.
Objective:Wehypothesized that variation in seleniumstatus inhealthyeuthyroidpostmenopausal
women is associated with differences in bone turnover, bone mineral density (BMD) and fracture
susceptibility.
Design: The Osteoporosis and Ultrasound Study (OPUS) is a 6-yr prospective study of fracture-related
factors.
Setting: The study was comprised of a population-based cohort from five European cities.
Participants: A total of 2374 postmenopausal women participated. Subjects with thyroid disease
and nonthyroidal illness and those receiving drugs affecting thyroid status or bone metabolism
were excluded, leaving a study population of 1144.
Interventions: There were no interventions.
Main Outcome Measures: We measured selenium (micrograms per liter); selenoprotein P (milli-
grams per liter); free T4 (picomoles per liter); free T3 (picomoles per liter); TSH (milliunits per liter);
bone turnover markers; BMD; and vertebral, hip, and nonvertebral fractures.
Results:Higher selenium levels were associatedwith higher hip BMDat study entry ( 0.072, P
0.004) and lower levels of bone formation (osteocalcin:   0.101, P  0.001; procollagen type
1 N-terminal propeptide: 0.074, P 0.013) and resorption markers (C-telopeptide of type 1
collagen: 0.058, P 0.050; N-telopeptide of type 1 collagen: 0.095, P 0.002). Higher
selenoprotein P was associated with higher hip ( 0.113, P 0.001) and lumbar spine BMD (
0.088, P 0.003) at study entry, higher hip BMD after the 6-yr follow-up ( 0.106, P 0.001) and
lower osteocalcin (0.077, P 0.009), C-telopeptide of type 1 collagen (0.075, P 0.012),
and N-telopeptide of type 1 collagen (  0.110, P  0.001).
Conclusion: Selenium status is inversely related to bone turnover and positively correlatedwith BMD
inhealthy euthyroidpostmenopausalwomen independent of thyroid status. (J Clin EndocrinolMetab
97: 4061–4070, 2012)
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The trace element selenium (Se) is required for develop-ment, well-being, and protection against age-related
disorders (1). Se bioavailability is dependent on nutrition
resulting in variation in Se sufficiency among populations.
Europe, including Germany, France, Scotland, and Eng-
land where this study was conducted, is relatively Se in-
sufficient comparedwith theUnited States andAsia (2, 3).
In humans, 25 genes encode selenoproteins (4), in
which the amino acid selenocysteine is incorporated dur-
ing protein translation by a specific tRNA. Although the
functions of several selenoproteins are unknown, many
have antioxidant activity and eliminate reactive oxygen
species (4). The iodothyronine deiodinases (DIO1–3) are
selenoenzymes involved in the regulation of circulating
and tissue thyroid status and incorporation of selenocys-
teine is essential for activity (5). DIO1 converts the pro-
hormone T4 to the active hormone T3 or inactivates T4 to
rT3 and contributes to iodine homeostasis and the circu-
lating pool of T3. DIO2 is expressed in T3 target tissues in
which it activatesT4 to control intracellularT3 availability
and regulate T3 action. DIO3 protects sensitive tissues
from excess thyroid hormone stimulation (5). Normal
function of the hypothalamic-pituitary-thyroid axis de-
pends on an adequate supply of iodine and activity of the
deiodinases (5).
The importance of Se availability is demonstrated by
patients with mutations in SBP2, encoding selenocysteine
insertion sequence-binding protein-2. Affected individu-
als display abnormal thyroid hormone metabolism and a
multisystem selenoprotein deficiency disorder that in-
cludes delayed skeletal development and linear growth (6,
7). The link between Se, thyroid function, and skeletal
disease is further evidenced by Kashin-Beck disease, an
osteoarthropathy endemic in Se- and iodine-deficient ar-
eas of Asia (8). Its etiology may include oxidative damage
to cartilage and bone due to Se deficiency or impaired
thyroid hormone effects on bone and cartilage because of
iodine deficiency. Alternatively, it may result from com-
bined deficiencies of both elements or from other envi-
ronmental factors (9).Mice with chondrocyte-specific de-
letion of Trsp encoding selenocysteine tRNA exhibit
delayed ossification, growth retardation, and chondrone-
crosis, demonstrating a direct role for selenoproteins in
skeletal development (10). Abnormal ossification and
growth are seen in rats with hypothyroidism (11) or
mice with thyroid hormone receptor deletion (12),
whereas mice with the deletion of Dio2 display brittle
bones (13). Dietary supplementation studies in rodents
reveal an important role for Se in bone but also identify
interactions between Se and iodine (14, 15). In human
populations, hypothyroidism and thyrotoxicosis are
each associated with an increased risk of fracture (16),
and variation in thyroid status across the reference
range is associatedwith changes in bonemineral density
(BMD) and fracture risk (17).
Overall, these studies reveal interactions between Se,
iodine, and thyroid function. Nevertheless, the exact role
of Se in bone development and maintenance is unknown,
and effects of Se could involve interactions with thyroid
hormones. We hypothesized that variation in Se status is
associated with differences in bone turnover, BMD, and
fracture susceptibility. To investigate this possibility, we
measured Se status in a population of healthy euthyroid
postmenopausal women and determined its relationship
to bone parameters and thyroid status.
Subjects and Methods
Osteoporosis and Ultrasound Study (OPUS)
OPUS is a prospective, population-based European study of
postmenopausalwomen. The study received approval according
to the Declaration of Helsinki. Written consent was obtained
from all subjects (17).
Biochemical measurements
Se concentrations were determined by x-ray fluorescence
spectroscopy (18). The method was validated with a Seronorm
standard (Sero AS, Billingstad, Norway) and was linear over a
range of 1:2, 1:5, or 1:10 dilutions. Selenoprotein P (SePP) is a
liver-derived Se storage and transport protein and an accurate
biomarker of Se status (18). Serum SePP concentrations were
determinedasdescribed (19). Inter- and intraassay coefficientsof
variationwere less than 10% for Se samples in the concentration
range 50–150 g/liter and approximately 7% for SePP samples
in the range 1.0–3.0 mg/liter.
SerumPTHand25-hydroxyvitaminDweredeterminedusing
an Immunodiagnostic Systems (IDS,Boldon,Tyne,&Wear,UK)
immunoassay system. Concentrations of TSH, free T4 (fT4) and
free T3 (fT3); the bone resorption marker type I collagen C-ter-
minal telopeptide (sCTX); the formation markers procollagen
type I N-terminal propeptide (PINP), and osteocalcin (OC); and
the urinary resorption marker N-terminal telopeptide of type I
collagen [uNTX; expressed as a ratio to creatinine (Cr) excretion
(uNTX to Cr)] were measured as described (17).
Physical measurements
Standardized BMDmeasurement at the hip and lumbar spine
was performed by dual-energy x-ray absorptiometry. The inci-
dent vertebral, hip and nonvertebral fractures were ascertained,
and grip strength and balance were assessed as described (17).
Study population
fT3, fT4, TSH, Se, and SePP reference ranges were calculated
for each decade of age (55–65, 65–75,75 yr) in 1565 healthy
euthyroid postmenopausal women. The 2.5th and 97.5th per-
centiles were calculated for fT4 and fT3. TSH, Se, and SePP
values were ranked and 2.5th and 97.5th percentiles calculated.
Toanalyze the relationships betweenSe andSePP levels andbone
parameters, individuals receiving drugs that interfere with bone
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metabolismwere excluded, leaving a final analysis population of
1144 (Fig. 1).
Statistics
Analyses were performed using SPSS version 15 (SPSS Inc.,
Chicago, IL). Normal distribution was evaluated using the Kol-
mogorov-Smirnov test, and nonparametric variables underwent
logarithmic transformation after which Se, SePP, TSH, 25-hy-
droxyvitamin D, PTH, sCTX, and uNTX to Cr ratio data sets
remained skewed. Thewhole data setwas examined for outlying
Se values to exclude subjects likely to be taking Se supplements.
Seven individuals with a median Se value of 351 g/liter (range
255-1243) were excluded.
Se and SePP levels were grouped into quintiles and the
Kruskal-Wallis test (K-W) conducted to explore relationships
betweenSeor SePPandBMD,bone turnovermarkers, pulse rate,
and grip strength. Stepwise regression analysis of relationships
between Se or SePP and thyroid status (fT4, fT3, TSH, fT4 to fT3
ratio) was performed.
Odds ratios for vertebral fracture in relation to Se and SePP
were determined using unadjusted and adjusted [for the follow-
ing: 1) 25-hydroxyvitamin D and PTH; 2) age, body mass index
(BMI), and BMD; 3) fT3, fT4, and TSH; and 4) all data sets]
logistic regression. Incident nonvertebral (includinghip) fracture
riskwasdeterminedbyCoxproportional hazardsmodeling.The
independent variable unit of analysis for the odds ratio and haz-
ards ratio was 1 g/liter for Se and 1 mg/liter for SePP. Stepwise
regression analysis of relationships between Se or SePP and
BMD, bone turnover, pulse rate, grip strength, and balance was
performed following adjustment for the following: 1) 25-hy-
droxyvitamin D and PTH; 2) age, BMI, and BMD; 3) thyroid
status; or 4) all. Analysis of relationships between thyroid status
and BMD, bone turnover, pulse rate, grip strength, and balance
was performed following adjustment for age, BMI, andBMD; Se
status; or both.
Results
Se and thyroid status in healthy postmenopausal
women
Todefineahealthy euthyroidpopulation, subjectswere
excluded if they were receiving T4 (n 237), antiepileptic
medications (n 19) or glucocorticoid medications (n
76); if they had renal disease (n  54), cancer (n  217),
overt thyroid disease (TSH  10 mU/liter and fT4  9
pmol/liter, or TSH 10 mU/liter and fT3 2.5 pmol/liter,
or TSH  0.1 mU/liter and fT3  6 pmol/liter) (n  20);
or had evidence of the sick euthyroid syndrome, defined as
fT3 less than 2.5 pmol/liter plus one or more of malab-
sorption, rheumatoid arthritis, bone disease other than
FIG. 1. Exclusion criteria to define populations of healthy euthyroid postmenopausal women and those women not receiving drugs affecting bone
metabolism.
TABLE 1. Age-related reference ranges for Se, SePP, and thyroid function tests
Analyte All women >55 yr 55–65 yr 66–75 yr >75 yr
Se (g/liter) 57.10–160.86 58.73–160.76 55.41–153.71 57.43–177.58
SePP (mg/liter) 1.98–4.85 2.02–4.85 2.03–4.84 1.99–4.80
TSH (mU/liter) 0.13–3.48 0.14–3.55 0.18–3.44 0.04–3.80
fT4 (pmol/liter) 9.07–16.62 8.83–16.44 9.16–16.50 9.56–17.00
fT3 (pmol/liter) 2.11–5.23 2.00–5.18 2.22–5.22 2.23–5.33
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osteoarthritis, psoriasis, or asthma (n 63).One hundred
eighty-nine subjectswithout availablemeasurements of Se
or SePP because of insufficient sample volume were ex-
cluded. Several subjects fulfilled two or more criteria re-
sulting in an exclusion of 809 subjects from the initial
group of 2374 to obtain a population of 1565 healthy
euthyroid postmenopausalwomen (Fig. 1), inwhich study
population reference intervals for Se, SePP, and normal
thyroid status were defined (Table 1). There were no dif-
ferences in years since the menopause, smoking, alcohol
consumption, prevalence of osteoarthritis, or a family his-
tory of fracture between this healthy euthyroid population
and the total population. There was a positive correlation
between Se and SePP concentrations (rho  0.324, P 
0.001) (Supplemental Fig. 1, published on The Endocrine
Society’s Journals Online web site at http://jcem.endojournals.
org). Sedecreased slightlywith age (K-W8.79;P0.012),
whereas SePP remained constant (K-W 3.08; P 0.214).
fT4 and fT3 increased with age (F  20.27, P  0.0001;
F  4.42, P  0.0012, respectively) and TSH remained
constant (K-W 0.047; P  0.977).
Analysis population
To determine the relationships between Se status and
bone parameters, individuals receiving drugs affecting
bonemetabolism (n 421)were excluded, to leave a final
analysis group of 1144 (Fig. 1 andTable 2). In the analysis
population, the following data were unavailable: lumbar
spine BMD at entry into the study in four individuals, hip
BMD at entry in three, lumbar spine BMD after 6 yr of
follow-up in 427, and hip BMD at follow-up in 425. The
paired BMD data were thus available in 709 women. 25-
hydroxyvitaminDandPTHwereunavailable in13and19
individuals, respectively, at entry and in 456 individuals at
follow-up. TSH, fT4, and fT3 were unavailable in one
individual, pulse rate in 29, balance in 35, grip strength in
187, OC in nine, PINP in nine, sCTX in nine, and uNTX
toCr ratio in 45 individuals. Thus, a complete data setwas
available in 535 individuals (Supplemental Table 1).
Inverse relationship between Se status and
thyroid hormones
After adjustment for age, higher fT4 and fT3 were as-
sociatedwith lower Se (fT4:0. 094,P 0. 001; fT3:
0.087, P 0.001) and SePP (fT4: 0.129, P
0. 001; fT3:   0. 172, P  0.001). There were no
associations between Se status and TSH (Se:   0.030,
P 0.232; SePP:  0.025, P 0.318). A higher fT4 to
fT3 ratiowas associatedwith higher SePP ( 0.082,P
0.001) but not Se (  0.032, P  0.206) (Table 3).
Relationship between Se status and vitamin D and
PTH
The 25-hydroxyvitamin D and PTH values were deter-
mined at baseline (Table 2) and after 6 yr of follow-up
(vitamin D, 20.82 ng/ml, n  688, range 8.56–46.21;
PTH,40.88pg/ml, n688, range17.26–106.82).Higher
vitamin D was associated with higher Se ( 0.110, P
0.001) but not with SePP ( 0.018, P 0.554). Higher
PTH was associated with lower Se (  0.125, P 
0.001) and SePP (0.074, P 0.015) (Supplemental
Table 2).





Age (yr) 67.8  7.0
BMI (kg/m2) 27.1  4.8
Years since menopause 18.7  9.0
Se (g/liter) 94.3 (range 54.4–161.2)
SePP (mg/liter) 3.2 (range 2.0–4.9)
TSH (mU/liter) 0.89 (range 0.14–3.64)
fT4 (pmol/liter) 12.8  1.9
fT3 (pmol/liter) 3.7  0.8
25-Hydroxyvitamin D (ng/ml) 19.53 (range 7.35–41.69)
PTH (pg/ml) 39.74 (range 13.38–98.67)
Lumbar spine BMD (mg/cm2) 1021  175
Hip BMD (mg/cm2) 863  144
OC (ng/ml) 26.2  10.7
PINP (ng/ml) 55.3  20.3
sCTX (ng/ml) 0.239 (range 0.011–0.759)
uNTX to Cr ratio (nM/mM) 50.3 (range 18.5–130.1)
Grip strength (kg) 18.5  5.3
Balance (m) 3.2  2.0
TABLE 3. Relationship between thyroid function tests and Se status
fT4 (pmol/liter) fT3 (pmol/liter)
Model R2
-Coefficient (95% CI)
(lower, upper, per SD change) P Model R2
-Coefficient (95% CI)
(lower, upper, per SD change) P
Se 0.010 0.101 (2.045, 0.699) <0.001 0.008 0.089 (4.447, 1.282) <0.001
SePP 0.017 0.131 (0.069, 0.031) <0.001 0.030 0.173 (0.200, 0.112) <0.001
Se 0.012 0.094 (1.967, 0.604) <0.001 0.010 0.087 (4.353, 1.186) 0.001
SePP 0.017 0.129 (0.069, 0.030) <0.001 0.030 0.172 (0.199, 0.110) <0.001
Statistically significant results are shown in bold. CI, Confidence interval.
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Higher hip BMD in women with higher Se and
SePP
Individuals with Se levels in the highest quintile had
higher hipBMDthanwomenwith Se in the lowest quintile
at study entry (KW 10.99, P  0.027). Individuals with
SePP in the highest quintile also had higher hip BMD at
study entry (KW 13.52, P  0.009). Figure 2 shows the
quintile plots relating hip and lumbar spine BMD at study
entry and after 6 yr of follow-up together with mean
changes in BMD in relation to Se and SePP. These plots
illustrate thepositive associationbetweenhipBMDandSe
and SePP across the reference range of Se and SePP con-
centrations and no relationship with lumbar spine BMD.
The mean hip and lumbar spine BMD values of women
with Se and SePP levels in the lowest and highest quintiles
are included in Supplemental Table 3.
Fracture risk is not related to Se or SePP
During 6 yr of follow-up, there were 43 incident ver-
tebral fractures in31 individuals and80nonvertebral frac-
tures, including seven hip fractures in seven individuals,
among the 1144 healthy euthyroid postmenopausal
women not receiving drugs affecting bone metabolism in
whom data were available. The unadjusted and adjusted
logistic regression indicated that Se and SePP were not
related to vertebral fracture (Supplemental Table 4). The
unadjusted and adjusted Cox proportional hazards anal-
ysis revealed the risk of incident nonvertebral fracture (in-
cluding hip fracture) was not related to differences in Se or
SePP. Separate analysis of hip fractures by Cox propor-
tional hazards was not possible because only seven inci-
dent fractures were recorded.
Selenium status is associated with pulse rate,
balance, and bone turnover
Pulse rate, grip strength, balance, and bone turnover
markers were investigated as possible factors underlying
associations between Se status and hip BMD. Individuals
with Se in the highest quintile had decreased uNTX to Cr
ratio (K-W 13.13, P  0.011) and better balance (K-W
12.29, P  0.015). Individuals with SePP in the highest
quintile had lower levels of OC (K-W 14.80, P 0.005),
PINP (K-W 10.04, P  0.038), uNTX to Cr ratio (K-W
13.69,P0.008) andan increasedpulse rate (K-W11.64,
P  0.020).
Adjusted regression
Stepwise regression was performed to investigate rela-
tionships between Se and SePPwith BMD, bone turnover,
and extraskeletal parameters (Table 4). After adjustment
for age, BMI, and smoking, higher Se was associated with
higher hip BMD at study entry (  0.072, P  0.004).
Higher Se was associated with lower markers of bone for-
mation (osteocalcin:   0.101, P  0.001; PINP:  
0.074, P  0.013) and resorption (procollagen type 1
N-terminal propeptide:0.058,P 0.050; uNTX to
Cr ratio: 0.095, P 0.002). Associations persisted
after adjustment for thyroid status, vitamin D, and PTH.
Higher Se was also associatedwith an increased pulse rate
but not other extraskeletal parameters after adjustment
for age, BMI, smoking and thyroid status, vitamin D, or
PTH (Table 4 and Supplemental Table 5).
After adjustment for age, BMI, and smoking, higher
SePP was associated with higher hip (  0.113, P 
0.001) and lumbar spine BMD ( 0.088, P 0.003) at
study entry, with higher hip BMD after 6 yr of follow up
( 0.106,P 0.001) andwith increased bone loss at the
lumbar spine (  0.106, P  0.001). Higher SePP was
associated with lower osteocalcin (  0.077, P 
0.009), procollagen type 1 N-terminal propeptide ( 
0.075, P 0.012) and uNTX to Cr ratio (0.110,
P  0.001). Associations persisted after adjustment for
thyroid status, vitaminD, and PTH.Higher SePPwas also
associatedwith increasedpulse rate and grip strength after
adjustment for age, BMI, smoking, vitamin D, and PTH,
but only the association with grip strength persisted after
adjustment for thyroid status (Table 4 and Supplemental
Table 5).
Effects of variation in thyroid status on BMD and
fracture risk are independent of Se status
We previously demonstrated that higher fT4 and fT3
levels within the reference range were associated with





(lower, upper, per SD change) P Model R2
-Coefficient (95% CI)
(lower, upper, per SD change) P
0.001 0.029 (0.489, 1.860) 0.253 0.001 0.030 (0.642, 2.593) 0.237 Unadjusted
0.001 0.024 (0.017, 0.049) 0.333 0.006 0.080 (0.028, 0.119) 0.001
0.004 0.030 (0.458, 1.889) 0.232 0.004 0.032 (0.574, 2.658) 0.206 Adjusted for age
0.002 0.025 (0.016, 0.050) 0.318 0.008 0.082 (0.029, 0.120) 0.001
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(17). In the current study, a different analysis population
was investigated because Se and SePPmeasurements were
available in only 1565 healthy euthyroid individuals com-
paredwith 1754 subjects originally and in 1144 compared
with1278after exclusionof subjects receivingbonedrugs.
Analysis of the current study population of 1144 individ-
uals again demonstrated associations between higher fT4
and fT3 levels with hip BMD and nonvertebral fracture
risk after adjustment for age, BMI, and
smoking (Supplemental Tables 6 and
7). Associations persisted after adjust-
ment for Se and SePP.
Discussion
These studies demonstrate that variation
in Se status is related to BMD and bone
turnover in healthy postmenopausal
women. There is controversy regarding
whether skeletal effects of Se are direct or
mediatedvia interactionswith iodine sta-
tus and thyroid function (8, 9, 15).Useof
a rigorously defined healthy euthyroid
population, enabling relationships be-
tween Se and bone to be investigated
without confounding effects of thyroid
dysfunction, is a strength of this study.
Logistic regressiondemonstrated that as-
sociationsbetweenSestatusandbonepa-
rameters were independent of changes in
fT3, fT4, or TSH. Associations between
thyroid status and bone parameterswere
independent of Se status.
Nevertheless, higher Se and SePP
levels were associated with extraskel-
etal parameters including increased
pulse rate (Se) and grip strength (SePP).
These represent novel associations be-
tween Se status and the cardiovascular
andmusculoskeletal systems that could
be direct or may reflect an interaction
between Se and the overall nutritional
status. Such findings complicate the un-
derstandingof the relationshipbetween
Se status and bone turnover and BMD.
Se levels correlated with SePP in ac-
cord with reliability of SePP as a marker
of Se status (18). Se, but not SePP, con-
centrations fell slightly with age. A study
of healthy Chinese (20) reported in-
creases in Se and SePP during the first de-
cade of life until constant levels were
maintained in adults. Small increases in Se andSePPwith age
have been reported in healthyU.S., Portuguese, andGerman
adults (19, 21, 22), but Sewas reported to decreasewith age
in a Finnish population (23). No studies have investigated
healthy euthyroid individuals, and reference ranges for Se
status in postmenopausal women have not been reported.
Nevertheless, the decrease in Se with age, but stability of
SePP, is noteworthy, although underlying reasons are un-
FIG. 2. Graphs showing hip (A–D) and lumbar spine (E–G) standardized BMD  95%
confidence intervals at the time of entry and after 6 yr of follow-up in relation to quintiles of
Se (A and E) and SePP (B and F) concentrations and graphs showing mean change in
standardized BMD  95% confidence intervals in relation to Se (C and G) and SePP (D and H)
concentrations.
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clear. A general possibility is that there may be decreasing
daily intake of Se-rich foods with age such as meat and sea-
food.Dietary intake,however, isanunreliable indicatorofSe
status, particularly because foods are obtained from all over
the world, and their Se content is variable and related to
source habitat and origin (24). A more specific possibility is
that SePP expression includes the translation of both full-
length protein and C-terminal truncated isoforms that lack
selenocysteine amino acids, resulting in reduced Se transport
capacity (25). It is unclear whether SePP biosynthesis is age
or gender dependent, but changes in SePP translation could
relate to declining estradiol concentrations in postmeno-
pausal women. Such a mechanism would account for the
decrease in Se concentration without apparent change in
SePP.
Alterations in Se and thyroid status were each associated
withboneparameters, but these relationshipsweremutually
exclusivewhen investigatedby logistic regression.Neverthe-
less, Se and SePPwere inversely correlatedwith fT3 and fT4
and positively correlated with the T4 to T3 ratio. Although
interactions between Se status and thyroid hormones have
been investigated in epidemiological studies with inconsis-
tent results, randomized intervention trials have not identi-
fied effects of Se supplementation on thyroid parameters
(26). A study of 41 patients with critical illness, sick euthy-
roid syndrome, and severe Se deficiency also reported no
effect of Se replacement on thyroid hormones (27). Never-
theless, thecurrent findingofan inverse relationshipbetween
Se and free thyroid hormones is consistent with a cross-sec-
tional study of 500 iodine-replete Iranian schoolchildren, in
which fT4 correlated negatively with Se (28).
Se and SePP were positively associated with changes in
BMD and inversely related to bone turnover. The findings
are consistent with studies reporting osteopenia in Se-defi-
cient rats (15), but there is a paucity of human data. Only
three cross-sectional studies have investigated relationships
between Se and BMD. They are limited by inadequate cri-
teria to exclude subjects with confounding factors including
thyroid disease, a lack of information on thyroid or iodine
status, and a lack of power. A study of 281 Chinese post-
menopausal women with marked Se insufficiency found no
relationship between Se and BMD in normal and osteopo-
rotic subgroups (29). In 107 Turkish postmenopausal
womenwithsimilarSe insufficiency,nodifference inSe levels
among subgroups with normal BMD, osteopenia, or osteo-
porosis was identified (30), and negative findings were re-
ported in 77Turkish postmenopausal, Se-deficient osteopo-
rotic women compared with 61 Se-deficient controls (31).
No studies have investigated the relationshipbetween Se sta-
tus andbone turnover.Thus, the current findings identify for
the first time that lower levels of Se and SePP within a large
population reference range are associated with higher bone
turnover and lower BMD in healthy postmenopausal
women.
In the context that Se and SePP were positively corre-
lated with BMD, it is reasonable to hypothesize that Se
deficiency would be related to fracture susceptibility.
However, no association between Se status and fracture
risk was identified. Se concentrations in the OPUS popu-
lation reflect mild Se insufficiency comparedwith concen-
trations reported in Se-replete populations (2). In the ab-
sence of overt Se deficiency in OPUS, it is not surprising
that no relationship between Se status and fracture risk
was identified, particularly because only small numbers of
incident fractures occurred in the healthy population dur-
ing 6 yr of prospective follow-up. A larger prospective
study will be required to include more fracture events.
There is little information to indicate themechanisms un-
derlying the relationship between Se status, bone turnover,
and BMD. IL-6 and other cytokines play a significant role in
the pathogenesis of osteoporosis (32), and Se exerts antiin-
flammatoryactions,mediated inpartby inhibitoryeffectson
IL-6 and cytokine activities (33), suggesting amechanismby
which Se could regulate bone turnover. In addition, bone
resorption generates a local burden of reactive oxygen spe-
cies, whichmay damage bone cells and extracellularmatrix,
leading to impaired bone remodeling and repair unless they
can be adequately eliminated (34). Accordingly, there is ev-
idence to support a critical role for reactive oxygen species in
osteoporosis (35). Expression of selenoproteins in bone-re-
sorbing osteoclasts and bone-forming osteoblasts (36, 37)
suggests Se status may be a limiting factor that regulates the
efficiency of reactive oxygen species clearance. Thus, it is
possible that a limiting threshold of Se is required for ade-
quate selenoprotein-mediated antioxidant activity and opti-
mal bone maintenance (38).
Although our studywas comprehensive, limitations re-
main.Althoughboth total Se and SePPwere determined in
parallel, providing a solid basis for assessment of Se status
(18, 39), measures of glutathione peroxidase (GPx) activ-
ity in plasma (extracellular GPx-3) or erythrocytes (cellu-
lar GPx-1) would provide additional indication of overall
antioxidant capacity (24). Such measurements were not
possible because only serum samples were available (pre-
cludingmeasurementofGPx1) and these hadbeen thawed
previously for other measurements, leading to unreliable
activity of GPx3. Se bioavailability is dependent on nutri-
tion, and although diet is an unreliable indicator of Se
status (24), it remains possible that the identified relation-
ship between Se status and bone metabolism could reflect
anunrelated effect of overall nutrition forwhich Semaybe
a biomarker. The OPUS did not include information re-
lating to diet. As discussed (17), blood samples were
drawn at the same time of the day to mitigate effects of
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diurnal variation. Nevertheless, samples were nonfasting,
and direct comparison of bone marker data with other
studies using morning fasting samples will continue to be
difficult. Furthermore, OPUS did not include information
relating todiabetesmellitus.Togetherwith the availability
only of nonfasting blood samples, this precluded the ex-
clusion of diabetic individuals. In addition, the OPUS da-
tabase does not provide information on the use of Se sup-
plements. To prevent confounding effects, individuals
with outlying high levels of Se greater than 250 g/liter
were excluded (n 7). Finally, the study was restricted to
postmenopausalwomen, and further studies are necessary
to determine whether the findings apply to other cohorts.
Overall,wedemonstrate that variation in Se statuswithin
the population reference range in healthy euthyroid post-
menopausalwomen is inversely related tobone turnoverand
positively correlated with BMD. These relationships were
independent of changes in thyroid status. The previously
identified relationship between physiological variation in
thyroid status and BMDand nonvertebral fracture (17) was
independent of changes in Se status. A next step will be to
investigate thetherapeuticutilityofSesupplementation.This
could be achieved by conducting a randomized controlled
trial of Se supplementation in postmenopausal womenwith
measurement of bone turnover as the end point. Such a trial
would need to be short term and cautious because, although
Se supplementation could be beneficial in individuals with
low Se status, it may have adverse effects in individuals who
are replete or have high Se status (40).
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TABLE 4. Relationship between Se, SePP, BMD, bone turnover, and extraskeletal parameters
Se (g/liter) Unadjusted Se (g/liter) Adjusted for age, BMI and smoking
Model R2
-Coefficient (95% CI)
(lower, upper, per SD change) P Model R2
-Coefficient (95% CI)
(lower, upper, per SD change) P
BMD
At study entry
Lumbar spine BMD 0.000 0.003 (0.389, 0.434) 0.915 0.135 0.002 (0.400, 0.374) 0.948
Hip BMD 0.009 0.094 (0.195, 0.829) 0.002 0.304 0.072 (0.123, 0.660) 0.004
6-yr follow-up
Lumbar spine BMD 0.000 0.015 (0.684, 0.470) 0.715 0.140 0.005 (0.579, 0.503) 0.890
Hip BMD 0.003 0.057 (0.083, 0.650) 0.129 0.307 0.036 (0.130, 0.488) 0.255
Change in lumbar spine BMD 0.002 0.047 (0.365, 0.095) 0.251 0.117 0.037 (0.325, 0.113) 0.342
Change in hip BMD 0.000 0.019 (0.102, 0.173) 0.610 0.017 0.015 (0.109, 0.167) 0.683
Bone turnover
OC 0.011 0.103 (0.065, 0.018) 0.001 0.042 0.101 (0.064, 0.017) <0.001
PINP 0.005 0.073 (0.101, 0.011) 0.014 0.021 0.074 (0.102, 0.012) 0.013
sCTX 0.004 0.061 (0.001, 0.000) 0.040 0.023 0.058 (0.001, 0.000) 0.050
uNTX to Cr ratio 0.010 0.101 (0.191, 0.050) 0.001 0.025 0.095 (0.185, 0.043) 0.002
Extraskeletal parameters
Pulse rate 0.005 0.067 (0.003, 0.048) 0.024 0.026 0.076 (0.007, 0.051) 0.011
Grip strength 0.000 0.011 (0.011, 0.015) 0.745 0.100 0.100 (0.014, 0.010) 0.773
Balance 0.004 0.062 (0.000, 0.009) 0.039 0.109 0.041 (0.001, 0.007) 0.151
SePP (mg/liter) Unadjusted SePP (mg/liter) Adjusted for age, BMI, and smoking
Model R2
-Coefficient (95% CI)
(lower, upper, per SD change) P Model R2
-Coefficient (95% CI)
(lower, upper, per SD change) P
BMD
At study entry
Lumbar spine BMD 0.007 0.081 (4.286, 32.791) 0.011 0.142 0.088 (6.688, 33.383) 0.003
Hip BMD 0.013 0.114 (10.523, 32.187) <0.001 0.312 0.113 (12.163, 30.364) <0.001
6-yr follow-up
Lumbar spine BMD 0.004 0.064 (3.746, 32.800) 0.119 0.145 0.068 (1.640, 32.506) 0.076
Hip BMD 0.011 0.106 (5.717, 30.700) 0.004 0.317 0.106 (7.770, 28.691) 0.001
Change in lumbar spine BMD 0.015 0.123 (18.444, 3.925) 0.003 0.128 0.115 (17.311, 3.537) 0.003
Change in hip BMD 0.003 0.051 (7.962, 1.454) 0.175 0.019 0.055 (8.211, 1.198) 0.144
Bone turnover
OC 0.006 0.075 (1.860, 0.241) 0.011 0.037 0.077 (1.876, 0.274) 0.009
PINP 0.002 0.044 (2.702, 0.374) 0.138 0.018 0.046 (2.738, 0.333) 0.125
sCTX 0.005 0.073 (0.043, 0.005) 0.014 0.025 0.075 (0.044, 0.006) 0.012
uNTX to Cr ratio 0.012 0.111 (6.968, 2.146) <0.001 0.029 0.110 (6.929, 2.116) <0.001
Extraskeletal parameters
Pulse rate 0.007 0.084 (0.334, 1.846) 0.005 0.028 0.089 (0.396, 1.902) 0.003
Grip strength 0.005 0.074 (0.951, 0.074) 0.022 0.106 0.078 (0.956, 0.121) 0.011
Balance 0.000 0.021 (0.209, 0.101) 0.494 0.108 0.028 (0.222, 0.073) 0.322
Statistically significant results are shown in bold. CI, Confidence interval; TFT, thyroid function tests.
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Supplemental Figure 1 
Graph showing a positive correlation between Se and SePP concentrations (Spearman's rank 
correlation coefficient rho=0.324, P<0.001). 
 
 










































































































































































































































































































































































































































SUPPLEMENTAL TABLE 1.  
Test variable Number 
Lumbar spine BMD at study entry 1140
Hip BMD at study entry 1141
Lumbar spine BMD at 6 years follow-up 717






25(OH)D at study entry 1131
25(OH)D at 6 years follow-up 688
PTH at study entry 1125








Incident vertebral fracture 728
Incident hip fracture 827
Incident non-vertebral fracture 793
Number of subjects in whom data was available for each variable
SUPPLEMENTAL TABLE 2. Relationship between 25(OH)D, PTH and Se status
 β coefficient (95% CI)  β coefficient (95% CI)
Model (lower, upper, Model (lower, upper, 
R2 per SD change) P R2 per SD change) P
Se 0.013 0.115 (0.152, 0.459) <0.001 0.017 -0.131 (-0.213, -0.082) <0.001
SePP 0.000 0.019 (-0.003, 0.006) 0.529 0.005 -0.073 (-0.004, 0.000) 0.014
Se 0.016 0.110 (0.138, 0.446) <0.001 0.019 -0.125 (-0.206, -0.074) <0.001
SePP 0.000 0.018 (0.003, 0.006) 0.554 0.005 0.074 (-0.004, 0.000) 0.015




SUPPLEMENTAL TABLE 3. 
 Lowest quintile Highest quintile Lowest quintile Highest quintile
69.50 (39.46 - 77.06) 128.43 (115.99 - 205.25) 2.35 (1.70 - 2.60) 4.29 (3.89 - 5.61)
Se - - 84.41 (46.20 - 149.12) 108.86 (59.53 - 190.48)*
SePP 2.83 (1.89 - 4.56) 3.55 (2.17 - 5.06)* - -
FT4 13.06±1.99 12.53±1.85* 13.18±1.85 12.36±1.92*
FT3   3.79±0.84  3.61±0.81   3.84±0.80  3.44±0.79*
TSH 0.82 (0.11 - 3.36) 0.91 (0.15 - 4.23) 0.95 (0.12 - 4.15) 1.04 (0.19 - 3.79)
25(OH)D 16.74 (6.67 - 38.97) 21.52 (7.87 - 43.61)* 17.85 (6.41 - 43.24) 19.38 (8.05 - 46.75)
PTH 42.90 (16.14 - 127.04) 36.74 (11.27 - 78.87)* 41.84 (10.35 - 127.67) 36.74 (15.72 - 87.04)
Lumbar spine BMD (study entry) 1031±175 1028±170 1013±174 1058±186
Hip BMD (study entry)    848±162     884±132 *   837±145     891±139 *
Lumbar spine BMD (follow-up) 1029±179 1027±160 1015±180 1040±185
Hip BMD (follow-up)   824±142  854±120   817±128  860±141
Change in lumbar spine BMD -2.4±74.3 -6.6±68.9     9.0±75.9 -21.4±67.7
Change in hip BMD -42.4±49.7 -39.4±48.8 -39.5±50.0 -45.0±47.6
*P≤0.05 highest vs lowest quintile
Se (ug/L) SePP (mg/L)
SUPPLEMENTAL TABLE 4. Relationship between Selenium status and fracture
 
Per unit change Per SD change P Per unit change Per SD change P
Prevalent vertebral fracture 0.99 (0.99 - 1.00) 0.77 (0.77 - 1.00) 0.375 - - -
Incident vertebral fracture 0.99 (0.98 - 1.01) 0.77 (0.59 - 1.30) 0.316 - - -
Incident non-vertebral fracture - - - 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.850
Prevalent vertebral fracture 1.00 (0.99 - 1.00) 1.00 (0.77 - 1.00) 0.316 - - -
Incident vertebral fracture 0.99 (0.98 - 1.01) 0.77 (0.59 - 1.30) 0.315 - - -
Incident non-vertebral fracture - - - 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.861
Prevalent vertebral fracture 1.00 (0.99 - 1.00) 1.00 (0.77 - 1.00) 0.376 - - -
Incident vertebral fracture 0.99 (0.98 - 1.01) 0.77 (0.59 - 1.30) 0.329 - - -
Incident non-vertebral fracture - - - 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.824
Prevalent vertebral fracture 0.99 (0.79 - 1.23) 0.99 (0.83 - 1.18) 0.910 - - -
Incident vertebral fracture 0.86 (0.53 - 1.39) 0.89 (0.60 - 1.30) 0.537 - - -
Incident non-vertebral fracture - - - 1.24 (0.90 - 1.70) 1.19 (0.92 - 1.53) 0.184
Prevalent vertebral fracture 1.00 (0.80 - 1.24) 1.00 (0.84 - 1.19) 0.971 - - -
Incident vertebral fracture 0.87 (0.53 - 1.41) 0.90 (0.60 - 1.32) 0.559 - - -
Incident non-vertebral fracture - - - 1.24 (0.90 - 1.70) 1.19 (0.92 - 1.53) 0.184
Prevalent vertebral fracture 1.01 (0.81 - 1.26) 1.01 (0.85 - 1.20) 0.953 - - -
Incident vertebral fracture 0.87(0.54 - 1.41) 0.90 (0.61 - 1.32) 0.562 - - -
Incident non-vertebral fracture - - - 1.29 (0.94 - 1.79) 1.23 (0.95 - 1.59) 0.121
Prevalent vertebral fracture 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.771 - - -
Incident vertebral fracture 0.99 (0.98 - 1.01) 0.77 (0.59 - 1.30) 0.366 - - -
Incident non-vertebral fracture - - - 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.688
Prevalent vertebral fracture 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.650 - - -
Incident vertebral fracture 0.99 (0.98 - 1.01) 0.77 (0.59 - 1.30) 0.365 - - -
Incident non-vertebral fracture - - - 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.688
Prevalent vertebral fracture 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.636 - - -
Incident vertebral fracture 0.99 (0.98 - 1.01) 0.77 (0.59 - 1.30) 0.369 - - -
Incident non-vertebral fracture - - - 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.600
Prevalent vertebral fracture 1.07 (0.85 - 1.34) 1.06 (0.88 - 1.26) 0.581 - - -
Incident vertebral fracture 0.84 (0.51 - 1.39) 0.87 (0.58 - 1.30) 0.504 - - -
Incident non-vertebral fracture - - - 1.32 (0.96 - 1.81) 1.25 (0.97 - 1.62) 0.092
Prevalent vertebral fracture 1.08 (0.86 - 1.36) 1.06 (0.89 - 1.30) 0.528 - - -
Incident vertebral fracture 0.85 (0.52 - 1.41) 0.88 (0.59 - 1.32) 0.533 - - -
Incident non-vertebral fracture - - - 1.32 (0.96 - 1.82) 1.25 (0.97 - 1.62) 0.089
Prevalent vertebral fracture 1.08 (0.86 - 1.35) 1.06 (0.89 - 1.27) 0.526 - - -
Incident vertebral fracture 0.85 (0.51 - 1.40) 0.88 (0.58 - 1.31) 0.517 - - -
Incident non-vertebral fracture - - - 1.42 (1.02 - 1.98) 1.32 (1.02 - 1.73) 0.037
Prevalent vertebral fracture 1.00 (0.99 - 1.00) 1.00 (0.77 -1.00) 0.377 - - -
Incident vertebral fracture 0.99 (0.98 - 1.01) 0.77 (0.59 - 1.30) 0.268 - - -
Incident non-vertebral fracture - - - 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.703
Prevalent vertebral fracture 0.99 (0.79 - 1.24) 0.99 (0.83 - 1.19) 0.947 - - -
Incident vertebral fracture 0.84 (0.52 - 1.38) 0.87 (0.59 - 1.29) 0.493 - - -
Incident non-vertebral fracture - - - 1.25 (0.90 - 1.73) 1.20 (0.92 - 1.55) 0.192
Prevalent vertebral fracture 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.736 - - -
Incident vertebral fracture 0.99 (0.98 - 1.01) 0.77 (0.59 - 1.30) 0.314 - - -
Incident non-vertebral fracture - - - 1.00 (0.99 - 1.01) 1.00 (0.77 - 1.30) 0.617
Prevalent vertebral fracture 1.06 (0.84 - 1.33) 1.05 (0.87 - 1.26) 0.629 - - -
Incident vertebral fracture 0.83 (0.50 - 1.37) 0.86 (0.57 - 1.29) 0.460 - - -
Incident non-vertebral fracture - - - 1.34 (0.96 - 1.86) 1.26 (0.97 - 1.64) 0.082
Units of measure are: Se, ug/liter; SePP, mg/liter. CI, Confidence interval.
SePP Adjusted for age, BMI and lumbar spine BMD
SePP
Adjusted for age, BMI,            
lumbar spine BMD and 
25(OH)D





Adjusted for                                 
FT3, FT4, TSH
Adjusted for                                 
FT3, FT4, TSH
Adjusted for age, BMI,                 
lumbar spine BMD,                       
FT3, FT4, TSH
Adjusted for age, BMI,                 





Logistic regression model Cox Proportional hazards model
HR (95% CI)
Unadjusted
Se Adjusted for PTH
Se Adjusted for age, BMI,            lumbar spine BMD and PTH
SePP Adjusted for 25(OH)D
SePP Adjusted for PTH
Se Adjusted for age, BMI and lumbar spine BMD
Se
Adjusted for age, BMI,            
lumbar spine BMD and 
25(OH)D
Se Adjusted for 25(OH)D
 β coefficient (95% CI)  β coefficient (95% CI)  β coefficient (95% CI)  β coefficient (95% CI)
Model (lower, upper, Model (lower, upper, Model (lower, upper, Model (lower, upper, 
R2 per SD change) P R2 per SD change) P R2 per SD change) P R2 per SD change) P
BMD
  At study entry 
   Lumbar spine BMD 0.003 -0.004 (-0.442, 0.393) 0.909 0.139 -0.010 (-0.460, 0.323) 0.732 0.000 0.004 (-0.395, 0.442) 0.911 0.135 -0.005 (-0.426, 0.360) 0.870
   Hip BMD 0.023 0.080 (0.118, 0.756) 0.007 0.317 0.059 (0.056, 0.593) 0.018 0.028 0.075 (0.092, 0.731) 0.012 0.325 0.053 (0.025, 0.561) 0.032
  6 years follow-up
    Lumbar spine BMD 0.002 -0.018 (-0.708, 0.457) 0.672 0.146 -0.010 (-0.614, 0.469) 0.793 0.000 -0.016 (-0.704, 0.472) 0.698 0.144 0.011 (-0.629, 0.465) 0.768
    Hip BMD 0.014 0.044 (-0.147, 0.591) 0.238 0.318 0.025 (-0.186, 0.432) 0.435 0.013 0.044 (-0.154, 0.590) 0.250 0.319 0.022 (-0.200, 0.4220 0.485
        Change in lumbar 0.008 -0.042 (-0.352, 0.112) 0.311 0.117 -0.035 (-0.321, 0.119) 0.367 0.002 -0.048 (-0.373, 0.097) 0.249 0.122 -0.045 (-0.350, 0.093) 0.255
        spine BMD
    Change in hip BMD 0.000 0.020 (-0.102, 0.177) 0.602 0.017 0.017 (-0.108, 0.171) 0.655 0.000 0.019 (-0.104, 0.177) 0.611 0.017 0.017 (-0.108, 0.172) 0.653
Bone turnover
        Osteocalcin 0.012 -0.099 (-0.064, -0.016) 0.001 0.043 -0.096 (-0.063, -0.015) 0.001 0.112 -0.061 (-0.047, -0.002) 0.033 0.153 -0.058 (-0.046, -0.001) 0.037
        P1NP  0.007 -0.067 (-0.097, -0.007) 0.025 0.025 -0.068 (-0.097, -0.007) 0.024 0.030 -0.052 (-0.085, 0.005) 0.080 0.053 -0.051 (-0.084, 0.005) 0.083
        sβCTX  0.004 -0.062 (-0.001, 0.000) 0.039 0.023 -0.060 (-0.001, 0.000) 0.047 0.079 -0.025 (-0.001, 0.000) 0.397 0.100 -0.023 (-0.001, 0.000) 0.423
        uNTXCr 0.010 -0.099 (-0.190, -0.047) 0.001 0.026 -0.093 (-0.183, -0.040) 0.002 0.030 -0.082 (-0.169, -0.027) 0.007 0.047 -0.077 (-0.162, -0.021) 0.011
Extraskeletal parameters
  At study entry
        Pulse rate 0.005 0.067 (0.003, 0.048) 0.026 0.026 0.074 (0.006, 0.050) 0.014 0.005 0.067 (0.003, 0.048) 0.028 0.027 0.072 (0.005, 0.050) 0.017
        Grip strength 0.008 0.000 (-0.013, 0.013) 0.994 0.104 -0.015 (-0.015, 0.009) 0.626 0.022 -0.009 (-0.015, 0.011) 0.779 0.112 -0.022 (-0.017, 0.008) 0.473
        Balance 0.009 0.053 (0.000, 0.009) 0.078 0.110 0.038 (-0.001, 0.007) 0.191 0.022 0.044 (-0.001, 0.008) 0.144 0.114 0.032 (-0.002, 0.007) 0.269
 β coefficient (95% CI) β coefficient (95% CI) β coefficient (95% CI) β coefficient (95% CI)
Model (lower, upper, Model (lower, upper, Model (lower, upper, Model (lower, upper, 
R2 per SD change) P R2 per SD change) P R2 per SD change) P R2 per SD change) P
BMD
  At study entry 
   Lumbar spine BMD 0.009 0.080 (3.955, 32.605) 0.012 0.147 0.087 (6.420, 33.191) 0.004 0.007 0.082 (4.229, 33.046) 0.011 0.143 0.086 (6.280, 33.231) 0.004
   Hip BMD 0.029 0.112 (10.099, 31.726) <0.001 0.326 0.112 (11.880, 29.978) <0.001 0.033 0.103 (8.544, 30.235) <0001 0.332 0.103 (10.273, 28.378) <0.001
  6 years follow-up
    Lumbar spine BMD 0.005 0.065 (-3.671, 33.143) 0.116 0.151 0.070 (-1.120, 33.013) 0.067 0.004 0.064 (-4.134, 33.010) 0.127 0.148 0.064 (-2.625, 31.840) 0.096
    Hip BMD 0.023 0.104 (5.361, 30.354) 0.005 0.328 0.105 (7.559, 28.354) 0.001 0.021 0.099 (4.357, 29.588) 0.008 0.328 0.099 (6.447, 27.418) 0.002
        Change in lumbar 0.022 -0.125 (-18.661, -4.073) 0.002 0.129 -0.116 (-17.416, -3.608) 0.003 0.015 -0.124 (-18.651, -3.895) 0.003 0.135 -0.120 (-17.848, -3972) 0.002
        spine BMD
    Change in hip BMD 0.003 -0.051 (-7.989, 1.489) 0.179 0.019 -0.054 (-8.210, 1.220) 0.146 0.003 -0.051 (-8.049, 1.508) 0.179 0.019 0.054 (-8.223, 1.285) 0.152
Bone turnover
        Osteocalcin 0.008 -0.075 (-1.851, -0.224) 0.012 0.040 -0.076 (-1.867, -0.262) 0.009 0.111 -0.051 (-1.490, 0.057) 0.069 0.152 -0.053 (-1.491, 0.024) 0.058
        P1NP  0.005 -0.043 (-2.682, 0.408) 0.149 0.022 -0.045 (-2.712, 0.359) 0.133 0.028 -0.032 (-2.385, 0.685) 0.278 0.051 -0.032 (-2.374, 0.667) 0.271
        sβCTX  0.005 -0.073 (-0.044, -0.005) 0.014 0.026 -0.075 (-0.044, -0.005) 0.012 0.081 -0.053 (-0.036, 0.001) 0.068 0.103 -0.054 (-0.037, 0.001) 0.057
        uNTXCr 0.013 -0.111 (-6.962, -2.112) <0.001 0.029 -0.110 (-6.919, -2.096) <0.001 0.034 -0.101 (-6.526, -1.706) 0.001 0.051 -0.100 (-6.470, -1.682) 0.001
Extraskeletal parameters
  At study entry
        Pulse rate 0.007 0.084 (0.328, 1.850) 0.005 0.028 0.089 (0.389, 1.899) 0.003 0.007 0.084 (0.318, 1.849) 0.006 0.029 0.087 (0.359, 1.877) 0.004
        Grip strength 0.014 -0.076 (-0.963, -0.086) 0.019 0.109 -0.079 (-0.963, -0.127) 0.011 0.029 -0.085 (-1.030, -0.154) 0.008 0.118 -0.086 (-1.013, -0.176) 0.005
        Balance 0.007 -0.022 (-0.214, 0.098) 0.464 0.110 -0.029 (-0.224, 0.072) 0.314 0.021 -0.031 (-0.237, 0.074) 0.301 0.115 -0.034 (-0.238, 0.059) 0.236
adjusted for PTH adjusted for age, BMI, smoking and PTH
Statistically significant results are shown in bold. CI, Confidence inetrval
adjusted for 25(OH)D adjusted for age, BMI, smoking and 25(OH)D
adjusted for PTH adjusted for age, BMI, smoking and PTH
SePP (mg/L) SePP (mg/L) SePP (mg/L) SePP (mg/L)
adjusted for 25(OH)D adjusted for age, BMI, smoking and 25(OH)D
SUPPLEMENTAL TABLE 5. Relationship between Se, SePP and BMD, bone turnover and extraskeletal parameters after adjustment for 25(OH)D and PTH
Se (ug/L) Se (ug/L) Se (ug/L) Se (ug/L)
SUPPLEMENTAL TABLE 6. Relationship between thyroid function tests, BMD, bone turnover and extraskeletal parameters
β coefficient (95% CI) β coefficient (95% CI) β coefficient (95% CI)
Model (lower, upper, Model (lower, upper, Model (lower, upper, 
R2 per SD change) P R2 per SD change) P R2 per SD change) P
BMD:
At study entry:
Lumbar spine BMD 0.136 -0.036 (-8.742, 2.140) 0.234 0.136 -0.030 (-18.764, 6.148) 0.321 0.137 -0.049 (-15.242, 1.295) 0.098
Hip BMD 0.301 -0.050 (-7.483, -0.030) 0.048 0.301 -0.040 (-15.758, 1.656) 0.112 0.299 -0.015 (-7.703, 4.077) 0.546
6 years follow-up:
Lumbar spine BMD 0.142 -0.044 (-11.175, 3.002) 0.258 0.143 0.051 (-5.232, 26.977) 0.185 0.142 -0.042 (-24.562, 6.886) 0.270
Hip BMD 0.312 -0.083 (-9.914, -1.382) 0.010 0.312 -0.076 (-22.270, -2.334) 0.016 0.307 0.030 (-3.458, 10.062) 0.338
Change in lumbar spine BMD 0.115 0.001 (-2.852, 2.901) 0.987 0.129 0.118 (3.586, 16.557) 0.002 0.115 -0.002 (-6.516, 6.244) 0.967
Change in hip BMD 0.021 -0.068 (-3.645, 0.176) 0.075 0.017 -0.029 (-6.219, 2.721) 0.443 0.020 0.059 (-0.574, 5.459) 0.112
Bone turnover
Osteocalcin 0.032 -0.011 (-0.389, 0.264) 0.707 0.032 0.005 (-0.701, 0.824) 0.874 0.036 -0.063 (-1.081, -0.052) 0.031
P1NP  0.016 0.007 (-0.552, 0.697) 0.820 0.016 -0.005 (-1.584, 1.334) 0.866 0.017 -0.040 (-1.667, 0.303) 0.175
sβCTX  0.021 0.033 (-0.004, 0.012) 0.280 0.023 -0.057 (-0.036, 0.000) 0.053 0.021 -0.039 (-0.021, 0.004) 0.191
uNTXCr 0.017 0.026 (-0.553, 1.415) 0.390 0.018 0.043 (-0.627, 3.965) 0.154 0.016 -0.011 (-1.833, 1.273) 0.723
Extra skeletal parameters:
At study entry:
Pulse rate 0.020 0.012 (-0.244, 0.370) 0.687 0.024 0.062 (0.042, 1.474) 0.038 0.020 -0.017 (-0.625, 0.345) 0.571
Grip strength 0.105 0.068 (0.018, 0.358) 0.030 0.126 0.161 (0.663, 1.446) <0.0001 0.102 -0.039 (-0.443, 0.094) 0.202
Balance 0.108 0.025 (-0.033, 0.087) 0.382 0.114 0.078 (0.056, 0.335) 0.006 0.107 0.004 (-0.089, 0.101) 0.901
β coefficient (95% CI) β coefficient (95% CI) β coefficient (95% CI)
Model (lower, upper, Model (lower, upper, Model (lower, upper, 
R2 per SD change) P R2 per SD change) P R2 per SD change) P
BMD:
At study entry:
Lumbar spine BMD 0.144 -0.025 (-7.798, 3.171) 0.408 0.143 -0.018 (-16.359, 8.759) 0.553 0.145 -0.049 (-15.145, 1.339) 0.101
Hip BMD 0.315 -0.033 (-6.213, 1.254) 0.193 0.314 -0.023 (-12.779, 4.670) 0.362 0.314 -0.019 (-8.110, 3.568) 0.446
6 years follow-up:
Lumbar spine BMD 0.147 -0.034 (-10.316, 4.056) 0.393 0.149 0.064 (-2.668, 29.916) 0.101 0.147 -0.044 (-24.936, 6.524) 0.251
Hip BMD 0.322 -0.069 (-9.009, -0.432) 0.031 0.321 -0.062 (-20.014, 0.031) 0.051 0.318 0.028 (-3.660, 9.782) 0.372
Change in lumbar spine BMD 0.129 -0.020 (-30628, 2.173) 0.622 0.139 0.102 (2.141, 15.242) 0.009 0.128 0.003 (-6.086, 6.622) 0.934
Change in hip BMD 0.026 -0.075 (-3.855, 0.002) 0.050 0.022 -0.037 (-6.749, 2.280) 0.332 0.024 0.059 (-0.580, 5.455) 0.113
Bone turnover
Osteocalcin 0.045 -0.027 (-0.476, 0.180) 0.376 0.044 -0.009 (-0.880, 0.654) 0.773 0.048 -0.059 (-1.037, -0.013) 0.045
P1NP  0.022 -0.003 (-0.658, 0.601) 0.929 0.022 -0.013 (-1.804, 1.138) 0.657 0.023 -0.037 (-1.610, 0.358) 0.212
sβCTX  0.027 0.021 (-0.005, 0.011) 0.494 0.032 -0.070 (-0.040, -0.004) 0.018 0.028 -0.036 (-0.020, 0.005) 0.225
uNTXCr 0.033 0.008 (-0.858, 1.117) 0.797 0.034 0.026 (-1.293, 3.316) 0.389 0.033 -0.006 (-1.699, 1.386) 0.842
Extra skeletal parameters:
At study entry:
Pulse rate 0.031 0.028 (-0.166, 0.452) 0.363 0.036 0.078 (0.231, 1.671) 0.010 0.031 -0.021 (-0.655, 0.311) 0.485
Grip strength 0.110 0.059 (-0.008, 0.335) 0.061 0.129 0.153 (0.609, 1.400) <0.0001 0.108 -0.038 (-0.439, 0.097) 0.212
Balance 0.111 0.025 (-0.035, 0.086) 0.402 0.117 0.077 (0.051, 0.333) 0.008 0.111 0.002 (-0.091, 0.098) 0.943
β coefficient (95% CI) β coefficient (95% CI) β coefficient (95% CI)
Model (lower, upper, Model (lower, upper, Model (lower, upper, 
R2 per SD change) P R2 per SD change) P R2 per SD change) P
BMD:
At study entry:
Lumbar spine BMD 0.010 -0.056 (-10.865, 0.630) 0.081 0.008 -0.025 (-18.755, 8.047) 0.433 0.008 -0.035 (-13.720, 3.910) 0.275
Hip BMD 0.028 -0.105 (-12.241, -3.547) <0.0001 0.020 -0.051 (-19.450, 1.245) 0.085 0.017 -0.002 (-7.155, 6.727) 0.952
6 years follow-up:
Lumbar spine BMD 0.007 -0.047 (-11.891, 3.258) 0.263 0.010 0.067 (-3.041, 31.688) 0.106 0.005 -0.012 (-19.242, 14.350) 0.775
Hip BMD 0.030 -0.136 (-14.342, -4.338) <0.0001 0.020 -0.088 (-26.243, -2.398) 0.019 0.014 0.047 (-2.889, 13.129) 0.210
Change in lumbar spine BMD 0.016 0.032 (-1.814, 4.210) 0.435 0.031 0.126 (3.856, 17.581) 0.002 0.016 0.007 (-6.064, 7.288) 0.857
Change in hip BMD 0.008 -0.065 (-3.569, 0.229) 0.085 0.005 -0.032 (-6.455, 2.561) 0.397 0.006 0.051 (-0.934, 5.102) 0.176
Bone turnover
Osteocalcin 0.013 -0.007 (-0.365, 0.287) 0.815 0.013 0.000 (-0.777, 0.768) 0.991 0.017 -0.067 (-1.115, -0.082) 0.023
P1NP  0.006 -0.002 (-0.639, 0.602) 0.954 0.006 -0.013 (-1.792, 1.149) 0.668 0.008 -0.044 (-1.736, 0.232) 0.134
sβCTX  0.009 0.041 (-0.002, 0.013) 0.172 0.011 -0.031 (-0.037, -0.001) 0.043 0.009 -0.041 (-0.021, 0.004) 0.169
uNTXCr 0.018 0.022 (-0.609, 1.336) 0.463 0.019 0.031 (-1.096, 3.512) 0.304 0.018 -0.010 (-1.802, 1.286) 0.743
Extra skeletal parameters:
At study entry:
Pulse rate 0.010 0.036 (-0.119, 0.492) 0.230 0.015 0.080 (0.251, 1.694) 0.008 0.009 -0.011 (-0.573, 0.397) 0.722
Grip strength 0.007 -0.003 (-0.185, 0.169) 0.931 0.023 0.128 (0.425, 1.258) <0.0001 0.008 -0.043 (-0.470, 0.093) 0.188
Balance 0.006 -0.023 (-0.087, 0.038) 0.445 0.009 0.059 (-0.001, 0.295) 0.052 0.006 -0.015 (-0.124, 0.075) 0.624
Adjusted for Se and SePP             Adjusted for Se and SePP             Adjusted for Se and SePP             
fT4 (pmol/liter)
fT4 (pmol/liter) fT3 (pmol/liter) TSH (mU/liter)
Adjusted for age, BMI, smoking,       
Se and SePP                        
Adjusted for age, BMI, smoking,       
Se and SePP                        
Adjusted for age, BMI, smoking,       
Se and SePP                        
fT3 (pmol/liter) TSH (mU/liter)
fT4 (pmol/liter) fT3 (pmol/liter) TSH (mU/liter)
Adjusted for age, BMI and smoking    Adjusted for age, BMI and smoking    Adjusted for age, BMI and smoking    
SUPPLEMENTAL TABLE 7. Relationship between thyroid function tests and fracture
 
Per unit change Per SD change P Per unit change Per SD change P
Prevalent vertebral fracture 1.06 (0.97-1.16) 1.12 (0.94-1.33) 0.208 - - -  
Incident vertebral fracture 0.92 (0.76-1.11) 0.85 (0.59-1.22) 0.378 - - - fT4 Unadjusted
Incident nonvertebral fracture - - - 0.86 (0.76-0.99) 0.75 (0.59-0.98) 0.029  
Prevalent vertebral fracture 0.89 (0.73-1.10) 0.91 (0.78-1.08) 0.288 - - -  
Incident vertebral fracture 1.04 (0.67-1.63) 1.03 (0.73-1.48) 0.850 - - - fT3 Unadjusted
Incident nonvertebral fracture - - - 0.72 (0.55-0.96) 0.77 (0.62-0.97) 0.024  
Prevalent vertebral fracture 1.04 (0.93-1.17) 1.05 (0.92-1.21) 0.496 - - -
Incident vertebral fracture 1.19 (0.84-1.67) 1.23 (0.81-0.85) 0.333 - - - TSH Unadjusted
Incident nonvertebral fracture - - - 1.16 (0.91-1.47) 1.19 (0.89-1.59) 0.240
Prevalent vertebral fracture 1.02 (0.95-1.12) 1.04 (0.91-1.24) 0.747 - - -
Incident vertebral fracture 0.92 (0.75-1.12) 0.85 (0.58-1.24) 0.392 - - - fT4
Incident nonvertebral fracture - - - 0.86 (0.75-0.99) 0.75 (0.58-0.98) 0.040
Prevalent vertebral fracture 0.83 (0.66-1.04) 0.86 (0.72-1.03) 0.100 - - -  
Incident vertebral fracture 1.09 (0.68-1.72) 1.07 (0.73-1.54) 0.727 - - - fT3
Incident nonvertebral fracture - - - 0.73 (0.54-0.98) 0.78 (0.61-0.98) 0.034
Prevalent vertebral fracture 1.02 (0.91-1.15) 1.02 (0.89-1.18) 0.705 - - -
Incident vertebral fracture 1.25 (0.88-1.76) 1.31 (0.86-1.97) 0.210 - - - TSH
Incident nonvertebral fracture - - - 1.35 (1.03-1.77) 1.43 (1.04-1.98) 0.032
Prevalent vertebral fracture 1.02 (0.93-1.12) 1.04 (0.87-1.24)  0.719 - - -
Incident vertebral fracture 0.90 (0.74-1.11) 0.82 (0.56-1.22) 0.327 - - - fT4
Incident nonvertebral fracture - - - 0.87 (0.75-0.99) 0.77 (0.58-0.98) 0.048
Prevalent vertebral fracture 0.83 (0.67-1.04) 0.86 (0.73-1.03) 0.109 - - -  
Incident vertebral fracture 1.06 (0.67-1.70) 1.05 (0.73-1.53) 0.797 - - - fT3
Incident nonvertebral fracture - - - 0.71 (0.83-0.95) 0.76 (0.86-0.96) 0.023
Prevalent vertebral fracture 1.02 (0.91-1.15) 1.02 (0.89-1.18) 0.690 - - -
Incident vertebral fracture 1.27 (0.90-1.81) 1.33 (0.88-2.04) 0.173 - - - TSH
Incident nonvertebral fracture - - - 1.35 (1.02-1.77) 1.43 (1.02-1.98) 0.034
Adjusted for age, BMI,    
lumbar spine BMD,          
Se and SePP
Adjusted for age, BMI,    
lumbar spine BMD,          
Se and SePP
Adjusted for age, BMI     
and lumbar spine BMD
Adjusted for age, BMI     
and lumbar spine BMD
Adjusted for age, BMI     
and lumbar spine BMD
Cox Proportional hazards model
OR (95% CI) HR (95% CI)
Logistic regression model
Adjusted for age, BMI,    
lumbar spine BMD,          
Se and SePP
